Focused on a single goal - to advance human brain health by bold Innovation
Dr. Rene Anand and Ms. Susan Mckay have developed a synthetic Neural Organoid Platform that is a synthetic mimic of the human central nervous system. It is a novel, first in class platform for studying human brain disease mechanisms and drug discovery, efficacy and safety testing.
Scientific Description of Neural Organoid Platform
LSX World Congress Presentation (2019)
Highlights of national and international press coverage
“A Harvard medical pioneer calls it “astounding” — an “incredible achievement” and a “quantum leap forward” in the battle against cancer, autism, Parkinson’s and Alzheimer’s” - CNN
“It is an extraordinary technological feat” - BBC
“A major step forward in the battle against autism, Parkinson’s, Alzheimer’s and some forms of cancer” - 6PR, Australia
"Breakthrough science from a Walk volunteer turned autism researcher" - Autism Speaks
“Far-Reaching Implications for Alzheimer’s Disease”- alzheimers.net
“Congratulations to the companies for winning the “Best University Startups 2016” – NCET2
“The research also opens the door to extremely personalized medicine” – NY Post
Advancing Alzheimer’s Research Without Animals, Could a lab-grown brain accelerate Alzheimer’s disease research?" - Physicians Committee for Responsible Medicine
Presentations at meetings
World CNS Summit, Boston, USA, February 2016
Cell Symposia “Aging and Metabolism”, Sitges, Spain, July 10th, 2016
Cell Symposia “10 years of iPSC”, Berkeley, USA, September 27th, 2016
Society for Neuroscience meeting, USA, November 15th, 2016
Booth # 4214:
NEURXSTEM is a specialty Contract Research Organization business commercializing the most advanced synthetic NEURAL ORGANOID PLATFORM available that mimics the human central nervous system. NEURXSTEM provides a transformational approach for studying human central nervous system disease biology, diagnostic development, and novel therapeutic discovery and development. We demonstrate, using iPSCs derived from skin cells, its utility to detect hallmarks of Alzheimers disease from a patient with APP gene duplication and autism and cancer susceptibility in Tuberous Sclerosis.
Neurxstem is developing products initially delivered using a specialized contract research organization model. The company will provide fee-based testing for drug targets and candidate toxicity, safety and efficacy using its synthetic Neural Organoid Platform™.
Neural Organoid Platform™ addresses significantly all the needs of potential clients for disease mechanism research, target identification, and TSE needs of big Pharma in a “one stop” platform that is highly predictive of human neural physiology.
Check ‘what we offer’ for details.